Project Grant R01HL189398
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $760K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Washington University $459,175 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance high-density diffuse optical tomography (HD-DOT) methods for perioperative neuromonitoring in children with congenital heart disease. The project develops HD-DOT technology to evaluate brain health through bedside neuroimaging of functional connectivity and cerebral oxygenation in perioperative settings. The...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital Corporation (Boston Children's Hospital) $673,345 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct THRIVE, a mechanistic analysis of transfusion and hemolysis-related injury in pediatric extracorporeal membrane oxygenation (ECMO). The award funds analysis of data from the TITRE multicenter trial, which enrolled over 220 children on ECMO and collected time-resolved plasma...
- The National Heart, Lung, and Blood Institute awarded The Washington University $545,304 on July 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research into extracellular vesicles as a prenatal rescue therapy for abnormal lung vasculature development in congenital diaphragmatic hernia. The project investigates stem cell-derived nanoparticles called extracellular vesicles that contain bioactive molecules critical for normal lung development. Preliminary...
- The National Institute of Child Health and Human Development awarded Loyola University of Chicago Health Sciences Campus $248,999 on June 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop single-cell multi-omics and machine learning approaches for identifying cellular and molecular mechanisms driving multiple organ dysfunction syndrome (MODS) deterioration in pediatric patients requiring extracorporeal membrane oxygenation (ECMO)...
- The National Heart, Lung, and Blood Institute awarded Inflo Medical Inc. $595,332 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to optimize its MOBYBOX extracorporeal membrane oxygenation (ECMO) platform for pediatric use. Inflo Medical is redesigning the MOBYBOX's gas exchanger and pulsatile displacement pump to reduce thrombogenicity and hemolysis in pediatric patients. The Phase I Small Business Innovation Research effort focuses on two complementary...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $773,237 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine the adoption, effectiveness, and system-level implications of veno-venous extracorporeal membrane oxygenation (ECMO) for treatment of severe acute respiratory failure. The research combines all-payer utilization data and private payer claims data to characterize ECMO adoption across U.S. hospitals, identify...
- The National Heart, Lung, and Blood Institute, under the Department of Health and Human Services National Institutes of Health, awarded The Washington University $768,128 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to mechanistically evaluate the role of oscillatory shear stress in deep vein thrombosis prevention. The recipient will conduct in vitro, in vivo, and human model studies to determine whether restoration of oscillatory shear stress in veins...
- The National Heart, Lung, and Blood Institute awarded The Washington University $1.902 million on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and correct immune-epithelial pathways underlying chronic muco-obstructive lung disease triggered by viral infection, allergen, smoke, or pollution exposure. The research identifies and characterizes a distinct subset of basal epithelial stem cells (basal-ESCs) that drive muco-obstructive disease phenotypes...
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $1,818,088 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how postnatal hypoxemia—reduced blood oxygen levels present in cyanotic congenital heart disease—impacts cardiac maturation and surgical recovery outcomes in pediatric patients. The project will examine the interaction between hypoxemia, myocardial immaturity, and postoperative complications through...
- The National Heart, Lung, and Blood Institute awarded The Washington University $169,140 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support immuno-metabolic research into chronic rejection after lung transplant. The funding supports investigation of the mechanistic drivers of bronchiolitis obliterans syndrome (BOS), a form of chronic rejection that is the major cause of death one year after lung transplant. The principal investigator, a lung transplant...